Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5850_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

30.08.2026

Размер:

49 Мб

Скачать

☆

<<< < Предыдущая 23 24 25 26 27 28 29 30 31 32 33 3435 / 5035 36 37 38 39 40 41 42 43 44 45 46 47 > Следующая >>>

330

https://t.me/medicina_free

Table 8 Potential phytoconstituents for inammatory bowel syndrome treatment and related diseases

Class/phytochemical constituents Pharmacological activity References Flavanoids—Naringenin Facilitate monocyte chemotaxis and colonic secretion of pro- inammatory factors

(ICAM-1, iNOS). Downregulate mRNA expression of TNF-α, Cox2, reduced the expression of NF-κB

Catechins

Rutin Decrease MPO activity, inhibit the IL-17, and NO syntheses, increase IL-4, reduce

Hesperetin Decrease the protein expression of p-JAK2 and P-STAT3, reduce the MPO, MDA,

Genistein

Anthocyanin Improve gut microbiota [292] Farrerol

Icariin

Quercetin

Myricetin and Kaempferol

Resveratrol

Apigenin

Luteolin Suppress the JAK/STAT pathway, the activation of the Nrf2 signalling pathway,

Terpenoid—Ginsenoside Inhibit macrophage activity, modulate Th1/Treg cell differentiation, reduce the

Limonin Reduce the disease activity index (DAI), downregulate the p-STAT3/miR-214 [121] Geraniol

Ursolic acid Suppress the JNK/JAK/STAT signalling pathway, upregulate T-SOD and CAT [298] Glycyrrhizic acid

Polysaccharides- Astragalus polysaccharide

Laminarin Suppress the proliferation of the pathogenic bacteria, decrease ICAM-1, IL-2 [301] Alkaloids—Oxymatrine Facilitate the Th1/Th2 cytokines balance, reduction of colonic IL-2 expression,

Piperine Reduce MPO and MDA activity, upregulate PXR, Cyp3aII, MDR1a, mRNA,

Boldine

Skimmianine

Aloperine Upregulate the Foxp3 levels, inhibit the colonic p-PI3K p85, p-mTOR, and p-Akt

N-methylcytisine

Improve Th1/Th2 balance and reduce TLR4/MyD88/NF-κB pathway expression. Suppress level the IL-6, MCP-1, TNF-α, reduce the MPO and LPO activity

the IL-1β, and suppress the proinammatory cytokines

and pro- inammatory levels Increase the protein expression of SOCS3

Facilitate the M1 macrophage to M2, reduced IL-6, TNFα, MCP-1, IL1β

Reduce the expression of TNF-α, IL-6, and IL-1β by suppressing the phosphorylation of NF-κB

Suppress p-STAT1, p-STAT3, and p-p65 expressions, inhibit the IL-6, TNF-α

Inhibit the cytokine production, induce NOS through suppression of NF-κB signalling pathway, regulate MPO activity, MDA level, increase GSH content, improve intestinal oxidative stress, decrease TNF-α, IFN-γ, IL-17A, IL-6, COX-2, iNOS, IL-1β levels Activate Nrf2, upregulate the expression of Interleukin-10 and reduce gut inammation

Decrease pro-inammatory factors such as IL-6, IL-1b, TNF- α, and iNOS Upregulate the expression of trefoil factor family3 (TFF3) gene, TGF-1β, and IL-10

Decrease IL-1β, TNF-α, IL-1β, IL-6, MPO activity, SphK1 activity. Downregulate NLRP-3, Wnt/β-catenin pathway, SUMO1

Induce protective cytokines and enzyme, reduce Cox-2, MMP-3, iNOS, TNF-α and IL-1b via inammasome pathway, decrease MPO activity

and increase the intestinal ora (Lactobacillus, Prevotella-9)

NLRP3 inammasome via the AMPK pathway and JNK activation, decrease IL-1β, IL-6, TNF-α, inhibit LPS and TLR4, and recover the balance of Th17, Tregs. Activate the TGF-β signalling pathway, suppress the MAPK and NF-κB signalling pathway

Decrease TNF- α, IL-1β, IL-6, MPO activity, iNOS and COX-2, inhibited NF-κB (p65)-DNA binding

Reduce IL-6 production, decrease the expression level IL-1β, IL-α, increase IL-10

Regulate TNF-α, IL-1β, and NFATc4 expressions, facilitate expression of GATA-3 and T-bet, balance, reduce the NF-ĸB phosphorylation and downregulate IL-6, IL-1β, and TNF-α

increase IL-10 levels, inhibition of p65 NF-kB and increase 2-β-adrenergic receptor (2BAR), decrease TNF-α and IL-6, ICAM-1

decrease ICAM, iNOS, IL-1β, MCP-1, IL-6, IL-1β, TNF-α, increase SOD activity

Reduce MPO and MDA activity, decrease TNF-α, IL-6, IL-17, N and F κB expression, and increase IκB-α expression

Reduce the expression levels of LBP, TNF-α, NFκB, TLR4, PGE2

expressions, upregulate the protein phosphatase 2A (PP2A) expression and suppress the PI3K/Akt/mTOR signal transduction pathway

Suppress pro-inammatory factors via activates NF-κB

E. R. Puppala et al.

[93]

[289]

[290]

[102]

[291]

[103]

[293]

[294]

[92]

[272]

[295]

[296]

[116]

[297]

[299]

[300]

[302]

[303]

[84]

[304]

[92]

[305]

Herbal Medicines fortheManagement ofIrritable Bowel Syndrome andConstipation Problem

https://t.me/medicina_free

(continued)

Table 8

Class/phytochemical constituents Pharmacological activity References Berberine

Theophylline Decrease the cytokine levels (IL-6, IL-1b, and TNF-a) and MPO activity and

Cavidine

Pentoxifylline Decrease the MDA levels, TGF-b1 MPO, MMP-1, and MMP-3 levels [309] Fatty acid—oleic acid

Linoleic acid The histological score is improved by decreasing MPO and alkaline phosphatase

Vitamin E—α-tocopherol

Iridoid

—Secoiridoids-

Oleuropein Acids—Sinapic acid Decrease MPO activity, facilitate SOD, GSH-Px, and catalase, and downregulate

Suppress STAT3, NF-κB signalling, reduce IL-1, IL-1β, IL-6, IL-12, TNF-α, TGF-β, and interferon-γ, upregulate IL-4 and IL-10 expressions. Downregulate the MPO and MDA activity, decrease the IκB degradation

activating the Nrf2/HO-1 signalling increase the IL-4, decrease AMCase and CHI3L1 expression

Reduce NF-κB, TNF-α, IL-6, MPO, and MDA activity, increase SOD activity

Decrease expression of p65, upregulate PPARγ

activity, TNFα, IL-1β, and LC n-6PUFA Decrease MPO, MDA, and alkaline phosphatase activity; inhibit NO, PGE2,

TNF-α, iNOS, COX-2 Reduce MDA, MPO, and NO levels and elevate SOD, CAT, and GPX levels.

Reduce the expression of Bax and increase the Bcl2 expression

the NLRP3 inammasome Increase the expression of ZO-1, occluding and Claudin-1

[306]

[307]

[308]

[310]

[311]

[312]

[313]

[314]

331

had overcome the challenges faced by pharmacokinetics and pharmacodynamics. These nanomedicines are available with unique characteristics such as a size range of ~ 100nm, several coated delivery systems, which include transferases; liposomes; dendrimer; solid lipids; microspheres, and cellular carriers such as recombinant bacteria and macrophages [316].

4.2 Natural Products Encapsulated Drug Delivery System

Recently, alkaloid, phenolic acids, and avonoid encapsulated nanoparticles (NPs) exhibited various immunemodulatory and anti-inammatory effects by altering the IL-1β, TNF-α, and NF-κB signalling. Curcumin, thymoquinone quercetin, piceatannol, andrographolide, berberine, silymarin, embelin, and resveratrol are natural alkaloids; avonoid, polyphenolic, and their acids from plants have shown various clinical pharmacological effects via reducing the production of NOD, caspase-1, NLRP3, MPO activity, IL-8, IL-6, MDA activity, Nrf2, HIF-αIL-1b, and TNF-a matrix metalloproteinase—2/3/9/13 Nrf2-, NF-κB, haeme oxygenase- 1 (HO-1), and STAT3-dependent signalling pathways [259, 261, 317]. β-Lactoglobulin-nanosphere, silk and pectin NPs, gold and silver NPs, chitosan-based hydrogel nanosystem, albumin-coated polymeric, liposomes solid lipid exosome, polymeric (PVP and CMC) NPs, and polyactidecoglycolide [318] were designed for prolonged and controlled release. In addition, an amphiphilic curcuminbased polymer is reported for IBS treatment.

Sometimes single natural products are not so practical for

treatment. Thus, a phyto-derived nanocarrier (size ~ 230nm)

[318] was used, including nano-size particles extracted from medicinal herbs or food. They have colossal biocompatibility and a stronghold in large industries. It is suggested that these phyto-derived nanocarriers, such as grape, ginger, blueberry, shitake mushroom exosomes, can transport across the cell membrane, can modulate intestinal tissue renewal processes, expression of inammatory genes, accumulate in the inamed colon, and exert potential therapeutic [319] Thus, these delivery systems can protect against liver toxicity and maintain the gut microbiota and pro-inammatory balance.

4.3 Fermented Formulation andDietary Supplements Used forInammatory Bowel Syndrome (IBS) andRelated Disorders

It is noteworthy to mention that the metabolism of gut microbiota or change in the intestinal metabolic state by some of the IBS conventional medicine has been reported. These conventional medications were reported to enhance carbohydrate metabolism and citrate cycle, which leads to bacterial sensitisation to oxidative stress, and decrease bacterial colonisation and polyphosphate level [320]. Thus, fermented formulations were used to overcome these side effects. FDA and WHO dened probiotics as live microorganisms which, in adequate amounts, can be benecial to humankind. In IBS, the primary cause of inammation is an unbalanced gut microbiota environment which facilitates the pathogenic pathways and restricts the movement of the bowels. Therefore, increasing the benecial bacteria subsequently decrease the inammation associated with IBS and other

332

https://t.me/medicina_free

Table 9 Various fermented and dietary formulations for the management of IBS

Fermented products Probiotic strain Activity References Lactic acid bacterium Pediococcus acidilactici Induce IL-10 [322] Dietary Lactobacillus L. plantarum Increase the total Bidobacteria and

Lactobacilli, decreased Enterococci and C. perfringens

Dietary probioticbacteria Bidobacteria and Lactobacillus, L. plantarum

(Lp91)

Bidobacterium strains B. bidum Bif1, Bif2, Bif3; Bidobacterium

longum

Lon4, Lon5, Lon6; Bidobacterium catenulatum Cat7, Cat8, Cat9; B. breve Bre10, Bre11, and Bidobacterium adolescentis Ado12

Fed Saccharomyces

boulardii

Bidobacterium breve

strain Yakult and Bidobacterium bidum strain Yakult

Administration of VSL#3

Dietary probiotic yogurt L. rhamnosus and L. reuteri

Dietary probiotics powder

Administered Lactobacillus spp.

Administered probiotics Lactobacillus casei, Lactobacillus acidophilus

Administration of Lactobacillus plantarum 299v (L. plantarum)

Dietary bre Soluble corn bre, STA-LITE III polydextrose,

Dietary pectin Pectin

S. boulardii

B. breve, B. bidum

Marketed product

Bidobacterium bidum

Lactobacillus paracasei, Lactobacillus reuteri

and Bidobacterium lactis L. pantarum

Bio gum, Pullulan, RROMITOR-resistant starch-75, inulin, orange pulp, guar gum, a mixture of orange pulp and guar gum, germinated barley foodstuff, fermentable dextrin bre, germinated barley foodstuff

Down-regulate TNF-α and COX-2 Up-regulate IL-10

Inhibit TNF-α, IL-8 production

Inhibit NF-κB signalling, inhibition of CD4+ T-cell inltration, reduce production of IFN-γ

Induce secretion of IL-10, inhibit TNF-αinduced secretion of IL-8

Decrease mucosal secretion of TNF-α, IFN-γ, prevent the epithelium from bacterial invasion

Decrease IL-12, TNF-α, IL-12

Inhibit IFN-γ, MCP-1, increase IL-10

Decrease TNF-α, reduced mucosal IL-12 mRNA

Reduce diarrhoea in B lactis, decrease TNF-α Production, iNOS, COX-2 expression

Decrease mucosal IL-12, IFN-γ

RROMITOR-resistant starch-75 and inulin decrease IFN-γ production; STA-LITE III polydextrose, bio gum, pullulan, and RROMITOR resistant, starch-75 up-regulate colonic PPAR-γ expression; a mixture of orange pulp and guar gum increases PGE2 level

Increase IFN-γ and IL-2, reduce TNF-α, GATA-3, IgG, and IgM

E. R. Puppala et al.

[323]

[324]

[325]

[326]

[327]

[328]

[329]

[330]

[324]

[301]

[331]

related diseases. Furthermore, these probiotics decrease visceral hypersensitivity and low-grade inammation and increase pro-inammatory cytokines and toll-like receptors to support the immunoregulatory effect. Pre-biotics are a substance utilised by probiotics, and postbiotics are nonliving microorganisms with or without their cell components that directly give health benets. Concerning this, the eightstrain combinations of Lactobacillus plantarum and

Lactobacillus paracasei subsp. paracasei, Lactobacillus aci- dophilus, Lactobacillus delbrueckii subsp bulgaricus, Bidobacterium breve, Bidobacterium longum subsp. longum, Bifdobacteriuminfantis, Bidobacteriumlongum subsp., and Streptococcus salivarius subsp. Streptococcus thermophilus are recommended and listed in Table9.; Apart

from these, prebiotics such as inulin, starch gum, dietary bre, pectin, and poly oligosaccharides [318] are reported to

have a potential effect in the treatment of IBS. This carbohydrate- rich diet includes long and short-chain carbohydrates (FOS and GOS) such as cellulose, hemicellulose, β-glucan, and fructans showing anti-inammatory and immunoregulatory activities. Additionally, facilitate myenteric and colonic motility, improving the total gut movement by providing the gelling of the intestinal tract. Primary sources such as bananas, beans, onion, raw leeks, asparagus, gum acacia, barleys, husks, seaweed, oats, dandelion, wheat, garlic, and fruit vegetables rich in high bre and carbohydrates are considered good sources of prebiotic bres and healthy diet [321].

The incorporation of bioactive compounds via nanotechnology provides a way of developing clinical candidates for health wellness. There is an existing gap in the literature for the toxicity risk of these bioactive molecules in long term.

Herbal Medicines fortheManagement ofIrritable Bowel Syndrome andConstipation Problem

https://t.me/medicina_free

333

5 Future Prospect

In response to the rising prevalence of IBS in Westernised countries, steadily increasing costs of IBS treatments, and the ineffectiveness of current IBS drug therapies, a substantial amount of research has been done to develop alternative therapies based on natural substances that are both highly effective and safe. A focus on recognising and addressing the dietary and environmental risk factors for IBS will be a priority in the future. In the search for natural alternative treatments for IBS, the introduction of unique cell models that can imitate the GI tract is thought to be a forthcoming model of research. It is also essential to have a thorough understanding of the pathogenic mechanisms underlying IBS which will enable the researchers to develop effective treatments for this ailment employing herbal medicines.

Clinical studies indicate that herbal medicines have a promising future in IBS therapy. A few issues must rst be rectied before administering the herbal medicine safely to the UC patients. There are still not enough large casecontrolled studies and reliable data on the specic mechanism of use of the herbs in invitro and invivo studies, and only a small number of UC patients have so far taken part in clinical trials using herbal medicine treatments. This could hasten the future research and development of herbal treatments for IBS.Additionally, since herbal formulations are a mixture of a wide variety of biological compounds, it is vital to know which component in the herbs provides the precise pharmacological effects, even in certain situations where the herb mixtures exhibit clinical effects. Thus, the determination of components of herb, dosage, and course of herb treatment plays a signicant role in their clinical employment. Furthermore, herbal therapy generally could carry risks and produce side effects such as liver and renal failure like other types of alternative therapy. Lead, arsenic, and mercury are just a few of the toxic ingredients found in many herb remedies. Therefore, there is a need for extensive research on the safety of herb medicines, particularly on long-term use.

6 Conclusion

From ancient times, these natural products, herbal extracts, and fermented formulations have been used to prevent and treat IBS and constipation. We now have a deeper insight into the genetics, mucosal changes, environmental triggers, and aberrant signalling that are the fundamental causes of IBS, constipation, and associated disorders. Novel therapies are being developed, yet approval of these new treatments must garner caution due to the unique and serious side effects that immunomodulator therapy entails. So, these diverse herbal formulations with complex functionality can be considered to overcome the drawbacks of conventional drugs. In addition, encapsulated bioactive molecules combination therapy is an

emerging strategy for IBS treatment to synergise the protective and therapeutic potential of IBS through various signalling pathways (cellular and molecular); improving the gut microbiota and can decrease the burden on the healthcare system and improving the quality of life. Their safe nutritional amount is required for clinical trials with larger sample sizes and periodic follow-ups for future medical benets.

Conicts of Interest

The authors declare that there are no conicts of interest to disclose.

References

1. Kirsner JB.Historical origins of current IBD concepts. World J Gastroenterol. 2001;7(2):175–84.

2. Hendrickson BA, Gokhale R, Cho JH.Clinical aspects and pathophysiology of inammatory bowel disease. Clin Microbiol Rev. 2002;15(1):79–94.

3. Puppala ER, Yalamarthi SS, Aochenlar SL, Prasad N, Syamprasad NP, Singh M, etal. Mesua assamica (King&Prain) kosterm. Bark ethanolic extract attenuates chronic restraint stress aggravated DSS-induced ulcerative colitis in mice via inhibition of NF-κB/ STAT3 and activation of HO-1/Nrf2/SIRT1 signaling pathways. J Ethnopharmacol. 2023;301:115765.

4. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF.Ulcerative colitis. Lancet. 2017;389(10080):1756–70.

5. Safar B, Sands D. Perianal Crohn’s disease. Clin Colon Rectal Surg. 2007;20(4):282–93.

6. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inammatory bowel disease. World J Gastroenterol. 2008;14(3):401–7.

7. Lee M, Chang EB.Inammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology. 2021;160(2):524–37.

8. Silva FAR, Rodrigues BL, Ayrizono MLS, Leal RF.The immunological basis of inammatory bowel disease. Gastroenterol Res Pract. 2016;2016:2097274.

9. Limdi JK. Dietary practices and inammatory bowel disease. Indian J Gastroenterol. 2018;37(4):284–92.

10. Kedia S, Ahuja V.Epidemiology of inammatory bowel disease in india: the great shift east. Inamm Intest Dis. 2017;2(2):102–15.

11. Park SH.Update on the epidemiology of inammatory bowel disease in Asia: where are we now? Intest Res. 2022;20(2):159–64.

12. Srinath AI, Walter C, Newara MC, Szigethy EM.Pain management in patients with inammatory bowel disease: insights for the clinician. Ther Adv Gastroenterol. 2012;5(5):339–57.

13. Cai Z, Wang S, Li J.Treatment of inammatory bowel disease: a comprehensive review. Front Med. 2021;8:765474.

14. Patange G, Giri S, Kharat J. Crohn’s disease: a review based on ayurveda and modern perspective. World J Pharm Res. 2019;8(10):1638–45.

15. Kalyankumarraju M, Puppala ER, Ahmed S, Jagadeesh Kumar G, Tene K, Syamprasad NP, et al. Zanthoxylum alatum Roxb. seed extract ameliorates stress aggravated DSS-induced ulcerative colitis in mice: plausible role on NF-κB signaling axis. J Ethnopharmacol. 2021;279:114385.

16. Garodia P, Ichikawa H, Malani N, Sethi G, Aggarwal BB.From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inammation and cancer. J Soc Integr Oncol. 2007;5(1):25–37.

334

https://t.me/medicina_free

E. R. Puppala et al.

17. Langhorst J, Schöls M, Cinar Z, Eilert R, Konk K, Paul A, et al. Comprehensive lifestyle-modication in patients with ulcerative colitis—a randomized controlled trial. J Clin Med. 2020;9(10):3087.

18. Zheng D, Liwinski T, Elinav E.Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–

506. https://doi.org/10.1038/s41422- 020- 0332- 7.

19. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36.

20. Pickard JM, Zeng MY, Caruso R, Núñez G.Gut microbiota: role in pathogen colonization, immune responses, and inammatory disease. Immunol Rev. 2017;279(1):70–89.

21. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, etal. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015;26:26050.

22. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, etal. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.

23. Mukhopadhya I, Segal JP, Carding SR, Hart AL, Hold GL.The gut virome: the “missing link” between gut bacteria and host immunity? Ther Adv Gastroenterol. 2019;12:1756284819836620.

24. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D.Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787–803.

25. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, etal. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24.

26. Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardiometabolic health. Gut Microbes. 2021;13(1):1–24. https://doi.org/

10.1080/19490976.2021.1897212.

27. Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: modulation of proliferation and inammation in homeostasis and disease. Cells. 2021;10(7):1775.

28. Hossain KS, Amarasena S, Mayengbam S.B vitamins and their roles in gut health. Microorganisms. 2022;10(6):1168.

29. Wu H-J, Wu E.The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3(1):4–14.

30. Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR.Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379.

31. Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inammatory bowel disease: current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci. 2021;21(3):270–83.

32. Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP.Dysbiosis in inammatory bowel disease: pathogenic role and potential therapeutic targets. Int J Mol Sci. 2022;23(7):3464.

33. Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G.Microbiota and drug response in inammatory bowel disease. Pathogens. 2021;10(2):211.

34. Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, etal. Microbiotas from humans with inammatory bowel disease alter the balance of gut Th17 and RORγt(+) regulatory T cells and exacerbate colitis in mice. Immunity. 2019;50(1):212–

224.e4.

35. Zeng MY, Inohara N, Nuñez G. Mechanisms of inammationdriven bacterial dysbiosis in the gut. Mucosal Immunol. 2017;10(1):18–26.

36. Gillespie W, Marya N, Fahed J, Leslie G, Patel K, Cave DR.Clostridium difcile in inammatory bowel disease: a retrospective study. Gastroenterol Res Pract. 2017;2017:4803262.

37. Mukherjee A, Lordan C, Ross RP, Cotter PD.Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 2020;12(1):1802866.

38. Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, etal. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255–61.

39. Miranda-Bautista J, Padilla-Suárez C, Bouza E, Muñoz P, Menchén L, Marín-Jiménez I.Listeria monocytogenes infection in inammatory bowel disease patients: case series and review of the literature. Eur J Gastroenterol Hepatol. 2014;26(11):1247–52.

40. Zhu C, Song K, Shen Z, Quan Y, Tan B, Luo W, etal. Roseburia intestinalis inhibits interleukin-17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep. 2018;17(6):7567–74.

41. Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inamm Bowel Dis. 2010;16(12):2034–42.

42. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, etal. The treatment-naive microbiome in newonset Crohn’s disease. Cell Host Microbe. 2014;15(3):382–92.

43. Zafar H, Saier MHJ.Gut bacteroides species in health and disease. Gut Microbes. 2021;13(1):1–20.

44. Zhang T, Ji X, Lu G, Zhang F. The potential of Akkermansia muciniphila in inammatory bowel disease. Appl Microbiol Biotechnol. 2021;105(14–15):5785–94.

45. Turroni F, Duranti S, Milani C, Lugli GA, van Sinderen D.Bidobacterium bidum: a key member of the early human gut microbiota. Microorganisms. 2019;7:544.

46. Clooney AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, Bernstein MT, Vagianos K, etal. Ranking microbiome variance in inammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021;70(3):499–510.

47. Elguezabal N, Chamorro S, Molina E, Garrido JM, Izeta A, Rodrigo L, et al. Lactase persistence, NOD2 status and Mycobacterium avium subsp. paratuberculosis infection associations to inammatory bowel disease. Gut Pathog. 2012;4:6.

48. Mottawea W, Chiang C-K, Mühlbauer M, Starr AE, Butcher J, Abujamel T, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun. 2016;7:13419.

49. Brennan CA, Garrett WS. Gut microbiota, inammation, and colorectal cancer. Annu Rev Microbiol. 2016;70:395–411.

50. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, etal. Adherent-invasive Escherichia coli in inammatory bowel disease. Gut. 2018;67(3):574–87.

51. Chandra H, Sharma KK, Tuovinen OH, Sun X, Shukla P.Pathobionts: mechanisms of survival, expansion, and interaction with host with a focus on Clostridioides difcile. Gut Microbes. 2021;13(1):1979882.

52. Zhu D, Sorg JA, Sun X.Clostridioides difcile biology: sporulation, germination, and corresponding therapies for C. difcile infection. Front Cell Infect Microbiol. 2018;8:29.

53. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli pathobionts associated with inammatory bowel disease. Clin Microbiol Rev. 2019;32(2):e00060-18.

54. Buttó LF, Schaubeck M, Haller D.Mechanisms of microbe-host interaction in Crohn’s disease: dysbiosis vs. pathobiont selection. Front Immunol. 2015;6:555.

55. Sugihara K, Kamada N.Diet-microbiota interactions in inammatory bowel disease. Nutrients. 2021;13(5):1533.

56. Chiba M, Nakane K, Komatsu M.Westernized diet is the most ubiquitous environmental factor in inammatory bowel disease. Perm J. 2019;23:18–107.

57. Paul B, Barnes S, Demark-Wahnefried W, Morrow C, Salvador C, Skibola C, etal. Inuences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin Epigenetics. 2015;7:112.

Herbal Medicines fortheManagement ofIrritable Bowel Syndrome andConstipation Problem

https://t.me/medicina_free

335

58. Na SY, Moon W.Perspectives on current and novel treatments for inammatory bowel disease. Gut Liver. 2019;13(6):604–16.

59. Debnath T, Kim DH, Lim BO.Natural products as a source of anti-inammatory agents associated with inammatory bowel disease. Molecules. 2013;18(6):7253–70.

60. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, etal. An evidence-based systematic review on medical therapies for inammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–31.

61. Lim WC, Wang Y, Macdonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2016;7(7):CD008870.

62. Li X, Lu C, Yang Y, Yu C, Rao Y.Site-specic targeted drug delivery systems for the treatment of inammatory bowel disease. Biomed Pharmacother. 2020;129:110486.

63. Hammad MA, Sulaiman SAS, Aziz NA, Noor DAM.Prescribing statins among patients with type 2 diabetes: the clinical gap between the guidelines and practice. J Res Med Sci. 2019;24(1):15.

64. Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino A, Debruyn JCC. Use of complementary and alternative medicine by patients with inammatory bowel disease. Inamm Bowel Dis. 2011;17(2):655–62.

65. Hung A, Kang N, Bollom A, Wolf JL, Lembo A.Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig Dis Sci. 2015;60(7):1883–8.

66. Pandurangan AK, Ismail S, Saadatdoust Z, Esa NM.Allicin alleviates dextran sodium sulfate- (DSS-)induced ulcerative colitis in BALB/c mice. Oxid Med Cell Longev. 2015;2015:605208.

67. El-Ashmawy NE, Khedr NF, El-Bahrawy HA, El-Adawy SA.Downregulation of iNOS and elevation of cAMP mediate the anti-inammatory effect of glabridin in rats with ulcerative colitis. Inammopharmacology. 2018;26(2):551–9.

68. Rezayat SM, Dehpour AR, Motamed SM, Yazdanparast M, Chamanara M, Sahebgharani M, etal. Foeniculum vulgare essential oil ameliorates acetic acid-induced colitis in rats through the inhibition of NF-kB pathway. Inammopharmacology. 2018;26(3):851–9.

69. Henriques DP, de Oliveira RR, Vanni J, de Lima HP, Otiti JV, Neves FRM, et al. Complementary and alternative medicine use in Brazilian patients with inammatory bowel disease. Arq Gastroenterol. 2022;59(3):375–82.

70. Wang XJ, Deng HZ, Jiang B, Yao H.The natural plant product sophocarpine ameliorates dextran sodium sulfate-induced colitis in mice by regulating cytokine balance. Int J Colorectal Dis. 2012;27(5):575–81.

71. Peng J, Zheng TT, Li X, Liang Y, Wang LJ, Huang YC, et al. Plant-derived alkaloids: the promising disease-modifying agents for inammatory bowel disease. Front Pharmacol. 2019;10:1–15.

72. Cheng H, Xia B, Zhang L, Zhou F, Zhang YX, Ye M, etal. Matrine improves 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Pharmacol Res. 2006;53(3):202–8.

73. Xia EQ, Cui B, Xu XR, Song Y, Ai XX, Bin LH. Microwaveassisted extraction of oxymatrine from sophora avescens. Molecules. 2011;16(9):7391–400.

74. Yao H, Shi Y, Yuan J, Sa R, Chen W, Wan X. Matrine protects against DSS-induced murine colitis by improving gut barrier integrity, inhibiting the PPAR-α signaling pathway, and modulating gut microbiota. Int Immunopharmacol. 2021;100:108091.

75. Fu X, Sun F, Wang F, Zhang J, Zheng B, Zhong J, etal. Aloperine protects mice against DSS-induced colitis by PP2A-mediated PI3K/Akt/mTOR signaling suppression. Mediators Inamm. 2017;2017:5706152.

76. Tahir M, Ali S, Zhang W, Lv B, Qiu W, Wang J. Aloperine: a potent modulator of crucial biological mechanisms in multiple diseases. Biomedicines. 2022;10(4):1–26.

77. Jia X, Zhang H, Jiang X, Lu Y, Liu W, Yu J.Proling and quantitation of alkaloids in different parts of Sophora alopecuroides L. extracts by high-performance liquid chromatography with electrospray ionisation ion mobility spectrometry detection. Phytochem Anal. 2021;32(6):1003–10.

78. Chen Q, Duan X, Fan H, Xu M, Tang Q, Zhang L, etal. Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. Int Immunopharmacol. 2017;53:149–57.

79. Zhang LC, Wang Y, Tong LC, Sun S, Liu WY, Zhang S, et al. Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inammation and oxidative stress. Exp Ther Med. 2017;13(6):3374–82.

80. Li C, Xi Y, Li S, Zhao Q, Cheng W, Wang Z, etal. Berberine ameliorates TNBS induced colitis by inhibiting inammatory responses and Th1/Th17 differentiation. Mol Immunol. 2015;67(2):444–54.

81. Liu Y, Liu X, Hua W, Wei Q, Fang X, Zhao Z, etal. Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-κB signaling pathway to protect against DSS-induced colitis. Int Immunopharmacol. 2018;57:121–31.

82. Li YH, Xiao HT, Hu DD, Fatima S, Lin CY, Mu HX, et al. Berberine ameliorates chronic relapsing dextran sulfate sodiuminduced colitis in C57BL/6 mice by suppressing Th17 responses. Pharmacol Res. 2016;110:227–39.

83. Luo Y, Liu M, Xia Y, Dai Y, Chou G, Wang Z. Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice. Phytomedicine. 2010;17(10):726–31.

84. Pandurangan AK, Mohebali N, Hasanpourghadi M, Looi CY, Mustafa MR, Mohd EN. Boldine suppresses dextran sulfate sodium-induced mouse experimental colitis: NF-κB and IL-6/ STAT3 as potential targets. BioFactors. 2016;42(3):247–58.

85. Zhou J, Qu F.Analysis of the extracts of Isatis tinctoria by new analytical approaches of HPLC, MS and NMR. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):33–45.

86. Rabelo Socca EA, Luiz-Ferreira A, De Faria FM, De Almeida AC, Dunder RJ, Manzo LP, etal. Inhibition of tumor necrosis factoralpha and cyclooxigenase-2 by isatin: a molecular mechanism of protection against TNBS-induced colitis in rats. Chem Biol Interact. 2014;209(1):48–55.

87. Shin DW, Lim BO. Nutritional interventions using functional foods and nutraceuticals to improve inammatory bowel disease. J Med Food. 2020;23(11):1136–45.

88. Lee S, Kim DC, Baek HY, Lee KD, Kim YC, Oh H. Antineuroinammatory effects of tryptanthrin from Polygonum tinctorium Lour. in lipopolysaccharide-stimulated BV2 microglial cells. Arch Pharm Res. 2018;41(4):419–30.

89. Micallef MJ, Iwaki K, Ishihara T, Ushio S, Aga M, Kunikata T, etal. The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol. 2002;2(4):565–78.

90. Wang Z, Wu X, Wang CL, Wang L, Sun C, Zhang DB, et al. Tryptanthrin protects mice against dextran sulfate sodium-induced colitis through inhibition of TNF-α/NF-κB and IL-6/STAT3 pathways. Molecules. 2018;23(5):1–13.

91. Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, et al. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr. 2013;110(4):599–608.

92. Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural antiinammatory compounds as drug candidates for inammatory bowel disease. Front Pharmacol. 2021;12:1–22.

93. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM.Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol. 2013;19(34):5633–44.

336

https://t.me/medicina_free

E. R. Puppala et al.

94. Ruiz Castro PA, Kogel U, Lo Sasso G, Phillips BW, Sewer A, Titz B, etal. Anatabine ameliorates intestinal inammation and reduces the production of pro-inammatory factors in a dextran sulfate sodium mouse model of colitis. J Inamm (Lond). 2020;17(1):1–17.

95. AlSharari SD, Akbarali HI, Abdullah RA, Shahab O, Auttachoat W, Ferreira GA, etal. Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther. 2013;344(1):207–17.

96. Hayashi S, Hamada T, Zaidi SF, Oshiro M, Lee J, Yamamoto T, etal. Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice. Am J Physiol Gastrointest Liver Physiol. 2014;307(10):G968–78.

97. Qin Z, Wan JJ, Sun Y, Wu T, Wang PY, Du P, etal. Nicotine protects against DSS colitis through regulating microRNA-124 and STAT3. J Mol Med. 2017;95(2):221–33.

98. Maruta K, Watanabe C, Hozumi H, Kurihara C, Furuhashi H, Takajo T, etal. Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. J Leukoc Biol. 2018;104(5):1013–22.

99. Ma H, He X, Yang Y, Li M, Hao D, Jia Z.The genus Epimedium: an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2011;134(3):519–41.

100. Wang Z, Wang D, Yang D, Zhen W, Zhang J, Peng S.The effect of icariin on bone metabolism and its potential clinical application. Osteoporos Int. 2018;29(3):535–44.

101. He C, Wang Z, Shi J. Pharmacological effects of icariin. In: Advances in pharmacology, vol. 87. 1st ed. Amsterdam: Elsevier;

2020. p.179–203.

102. Elhennawy MG, Abdelaleem EA, Zaki AA, Mohamed WR. Cinnamaldehyde and hesperetin attenuate TNBS-induced ulcerative colitis in rats through modulation of the JAk2/STAT3/ SOCS3 pathway. J Biochem Mol Toxicol. 2021;35(5):1–11.

103. Ran X, Li Y, Chen G, Fu S, He D, Huang B, etal. Farrerol ameliorates TNBS-induced colonic inammation by inhibiting ERK1/2, JNK1/2, and NF-κB signaling pathway. Int J Mol Sci. 2018;19(7):1–14.

104. Dodda D, Chhajed R, Mishra J, Padhy M. Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inammatory bowel disease like symptoms in rats: role of quercetin. Indian J Pharmacol. 2014;46(3):286–91.

105. Dodda D, Chhajed R, Mishra J. Protective effect of quercetin against acetic acid induced inammatory bowel disease (IBD) like symptoms in rats: possible morphological and biochemical alterations. Pharmacol Rep. 2014;66(1):169–73.

106. Jones JR, Lebar MD, Jinwal UK, Abisambra JF, Koren J, Blair L, etal. The diarylheptanoid (+)-aR,11S-myricanol and two avones from bayberry (Myrica cerifera) destabilize the microtubuleassociated protein tau. J Nat Prod. 2011;74(1):38–44.

107. Imran M, Salehi B, Shari-Rad J, Gondal TA, Saeed F, Imran A, etal. Kaempferol: a key emphasis to its anticancer potential. Molecules. 2019;24(12):1–16.

108. Semwal DK, Semwal RB, Combrinck S, Viljoen A. Myricetin: a dietary molecule with diverse biological activities. Nutrients. 2016;8(2):1–31.

109. Qu X, Li Q, Song Y, Xue A, Liu Y, Qi D, etal. Potential of myricetin to restore the immune balance in dextran sulfate sodiuminduced acute murine ulcerative colitis. J Pharm Pharmacol. 2020;72(1):92–100.

110. Qi LW, Wang CZ, Yuan CS. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry. 2011;72(8):689–99.

111. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, etal. Brief communication: American ginseng reduces warfarin’s effect in healthy patients. A randomized, controlled trial. Ann Intern Med. 2004;141(1):23–8.

112. Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inammation. Biochem Pharmacol. 2011;82(3):278–86.

113. Poudyal D, Le PM, Davis T, Hofseth AB, Chumanevich A, Chumanevich AA, et al. A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: antiinammatory and proapoptotic mechanisms. Cancer Prev Res. 2012;5(4):685–96.

114. Dai D, Zhang CF, Williams S, Yuan CS, Wang CZ.Ginseng on cancer: potential role in modulating inammation-mediated angiogenesis. Am J Chin Med. 2017;45(1):13–22.

115. Yang XL, Guo TK, Wang YH, Gao MT, Qin H, Wu YJ.Therapeutic effect of ginsenoside Rd in rats with TNBS-induced recurrent ulcerative colitis. Arch Pharm Res. 2012;35(7):1231–9.

116. Liu C, Wang J, Yang Y, Liu X, Zhu Y, Zou J, etal. Ginsenoside Rd ameliorates colitis by inducing p62-driven mitophagy-mediated NLRP3 inammasome inactivation in mice. Biochem Pharmacol. 2018;155:366–79.

117. Yang XL, Guo TK, Wang YH, Huang YH, Liu X, Wang XX, etal. Ginsenoside Rd attenuates the inammatory response via modulating p38 and JNK signaling pathways in rats with TNBS-induced relapsing colitis. Int Immunopharmacol. 2012;12(2):408–14.

118. Yang N, Liang G, Lin J, Zhang S, Lin Q, Ji X, etal. Ginsenoside Rd therapy improves histological and functional recovery in a rat model of inammatory bowel disease. Phytother Res. 2020;34(11):3019–28.

119. Ye H, Wu Q, Zhu Y, Guo C, Zheng X.Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFβ signaling. Mol Biol Rep. 2014;41(8):5485–90.

120. Tian M, Ma P, Zhang Y, Mi Y, Fan D.Ginsenoside Rk3 alleviated DSS-induced ulcerative colitis by protecting colon barrier and inhibiting NLRP3 inammasome pathway. Int Immunopharmacol. 2020;85:106645.

121. Liu S, Zhang S, Lv X, Lu J, Ren C, Zeng Z, etal. Limonin ameliorates ulcerative colitis by regulating STAT3/miR-214 signaling pathway. Int Immunopharmacol. 2019;75:105768.

122. Song C, Chen J, Li X, Yang R, Cao X, Zhou L, etal. Limonin ameliorates dextran sulfate sodium-induced chronic colitis in mice by inhibiting PERK-ATF4-CHOP pathway of ER stress and NF-κB signaling. Int Immunopharmacol. 2021;90:107161.

123. Busbee PB, Menzel L, Alrafas HR, Dopkins N, Becker W, Miranda K, etal. Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22-dependent manner. JCI Insight. 2020;5(1):1–18.

124. Huang Z, Jiang Y, Yang Y, Shao J, Sun X, Chen J, et al. 3,3′-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction. Mol Immunol. 2013;53(4):335–44.

125. Lv Q, Qiao SM, Xia Y, Shi C, Xia YF, Chou GX, etal. Norisoboldine ameliorates DSS-induced ulcerative colitis in mice through induction of regulatory T cells in colons. Int Immunopharmacol. 2015;29(2):787–97.

126. Lv Q, Wang K, Qiao S, Yang L, Xin Y, Dai Y, etal. Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD+/SIRT1/ SUV39H1/H3K9me3 signaling pathway article. Cell Death Dis. 2018;9(3):258.

127. Liang YN, Yu JG, Zhang DB, Zhang Z, Ren LL, Li LH, et al. Indigo naturalis ameliorates dextran sulfate sodium-induced colitis in mice by modulating the intestinal microbiota community. Molecules. 2019;24(22):4086.

128. Chang Y, Zhai L, Peng J, Wu H, Bian Z, Xiao H.Phytochemicals as regulators of Th17/Treg balance in inammatory bowel diseases. Biomed Pharmacother. 2021;141:111931.

129. Xiao HT, Peng J, Hu DD, Lin CY, Du B, Tsang SW, etal. Qing-dai powder promotes recovery of colitis by inhibiting inammatory

Herbal Medicines fortheManagement ofIrritable Bowel Syndrome andConstipation Problem

https://t.me/medicina_free

337

responses of colonic macrophages in dextran sulfate sodiumtreated mice. Chin Med. 2015;10(1):1–13.

130. Yang L, Li X, Huang W, Rao X, Lai Y. Pharmacological properties of indirubin and its derivatives. Biomed Pharmacother. 2022;151:113112.

131. Gao W, Zhang L, Wang X, Yu L, Wang C, Gong Y.The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice. Biochem Cell Biol. 2018;96(5):636–45.

132. Sawaya ACF, Abreu IN, Andreazza NL, Eberlin MN, Mazzafera P.HPLC-ESI-MS/MS of imidazole alkaloids in Pilocarpus microphyllus. Molecules. 2008;13(7):1518–29.

133. Rodrigues de Carvalho L, de Brito TV, Simião da C, Júnior J, José Dias Júnior G, de Aguiar Magalhãres D, Guimarães Sousa S, etal. Epiisopiloturine, an imidazole alkaloid, reverses inammation and lipid peroxidation parameters in the Crohn disease model induced by trinitrobenzenosulfonic acid in Wistar rats. Biomed Pharmacother. 2018;102:278–85.

134. Guo G, Shi F, Zhu J, Shao Y, Gong W, Zhou G, et al. Piperine, a functional food alkaloid, exhibits inhibitory potential against TNBS-induced colitis via the inhibition of IκB-α/NF-κB and induces tight junction protein (claudin-1, occludin, and ZO-1) signaling pathway in experimental mice. Hum Exp Toxicol. 2020;39(4):477–91.

135. Bai R, Jie X, Yao C, Xie Y.Discovery of small-molecule candidates against inammatory bowel disease. Eur J Med Chem. 2020;185:111805.

136. Guo BJ, Bian ZX, Qiu HC, Wang YT, Wang Y.Biological and clinical implications of herbal medicine and natural products for the treatment of inammatory bowel disease. Ann N Y Acad Sci. 2017;1401(1):37–48.

137. Gupta RA, Motiwala MN, Dumore NG, Danao KR, Ganjare AB.Effect of piperine on inhibition of FFA induced TLR4 mediated inammation and amelioration of acetic acid induced ulcerative colitis in mice. J Ethnopharmacol. 2015;164:239–46.

138. Dejban P, Nikravangolsed N, Chamanara M, Dehpour A, Rashidian A.The role of medicinal products in the treatment of inammatory bowel diseases (IBD) through inhibition of TLR4/ NF-kappaB pathway. Phytother Res. 2021;35(2):835–45.

139. Kang GD, Kim DH.Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance. J Ethnopharmacol. 2016;189:175–85.

140. Wang H, Gu J, Hou X, Chen J, Yang N, Liu Y, et al. Antiinammatory effect of miltirone on inammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway. Biomed Pharmacother. 2017;85:531–40.

141. Yue W, Liu Y, Li X, Lv L, Huang J, Liu J.Curcumin ameliorates dextran sulfate sodium-induced colitis in mice via regulation of autophagy and intestinal immunity. Turk J Gastroenterol. 2019;30(3):290–8.

142. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325–48.

143. Luis PB, Gordon ON, Nakashima F, Joseph AI, Shibata T, Uchida K, etal. Oxidative metabolism of curcumin-glucuronide by peroxidases and isolated human leukocytes. Biochem Pharmacol. 2017;132:143–9.

144. Mouzaoui S, Banerjee S, Djerdjouri B. Low-dose curcumin reduced TNBS-associated mucin depleted foci in mice by scavenging superoxide anion and lipid peroxides, rebalancing matrix NO synthase and aconitase activities, and recoupling mitochondria. Inammopharmacology. 2020;28(4):949–65.

145. Dubey P, Begum RF, Chitra V, Mrinalini R, Gunasekaran H, Sumithra M.Formulation, standardization, and preclinical evalua-

tion of polyherbal suspension against inammatory bowel disease. J Nat Remedies. 2022;22(3):412–23.

146. Mashtoub S, Hoang BV, Vu M, Lymn KA, Feinle-Bisset C, Howarth GS.Clinical and structural effects of traditional Chinese medicine and the herbal preparation, iberogast, in a rat model of ulcerative colitis. J Evid Based Complementary Altern Med. 2014;19(1):10–9.

147. Saba E, Lee YY, Kim M, Hyun SH, Park CK, Son E, et al. A novel herbal formulation consisting of red ginseng extract and Epimedium koreanum Nakai-attenuated dextran sulfate sodiuminduced colitis in mice. J Ginseng Res. 2020;44(6):833–42.

148. Gautam MK, Goel S, Ghatule RR, Singh A, Nath G, Goel RK. Curative effect of Terminalia chebula extract on acetic acid-induced experimental colitis: role of antioxidants, free radicals and acute inammatory marker. Inammopharmacology. 2013;21(5):377–83.

149. Tsang SW, Ip SP, Wu JCY, Ng SC, Yung KKL, Bian ZX.A Chinese medicinal formulation ameliorates dextran sulfate sodium-induced experimental colitis by suppressing the activity of nuclear factorkappaB signaling. J Ethnopharmacol. 2015;162:20–30.

150. Shin MS, Kim SB, Lee J, Choi HS, Park J, Park JY, et al. Benecial effect of herbal formulation KM1608 on inammatory bowl diseases: a preliminary experimental study. Molecules. 2018;23(8):1–14.

151. Koppikar SJ, Jagtap SD, Devarshi PP, Jangle NM, Awad VB, Wele AA, etal. Triphala, an ayurvedic formulation improves the antioxidant status on TNBS induced IBD in rats. Eur J Integr Med. 2014;6(6):646–56.

152. Raju A, Rayudu V.Effect of Triphala on dextran sulphate sodiuminduced colitis in rats. Ayu. 2014;35(3):333.

153. Wu Z-C, Zhao Z-L, Deng J-P, Huang J-T, Wang Y-F, Wang Z-P. Sanhuang Shu’ai decoction alleviates DSS-induced ulcerative colitis via regulation of gut microbiota, inammatory mediators and cytokines. Biomed Pharmacother. 2020;125:109934.

154. Wu F, Shao Q, Hu M, Zhao Y, Dong R, Fang K, etal. Wu-MeiWan ameliorates chronic colitis-associated intestinal brosis through inhibiting broblast activation. J Ethnopharmacol. 2020;252:112580.

155. Zhai L, Peng J, Zhuang M, Chang Y-Y, Cheng KW, Ning Z-W, et al. Therapeutic effects and mechanisms of Zhen-Wu-Bu-Qi decoction on dextran sulfate sodium-induced chronic colitis in mice assessed by multi-omics approaches. Phytomedicine. 2022;99:154001.

156. Wadie W, Abdel-Aziz H, Zaki HF, Kelber O, Weiser D, Khayyal MT.STW 5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis. 2012;27(11):1445–53.

157. Cota D, Mishra S, Shengule S.Arjunarishta alleviates experimental colitis via suppressing proinammatory cytokine expression, modulating gut microbiota and enhancing antioxidant effect. Mol Biol Rep. 2020;47(9):7049–59.

158. Zhang M, Fan H, Tan S, Tang Q, Liu X, Zuo D, etal. The Chinese medicinal herb decoction QRZSLXF enhances anti-inammatory effect in TNBS-induced colitis via balancing Th17/Tregs differentiation. J Ethnopharmacol. 2020;251:112549.

159. Peregoy JA, Clarke TC, Jones LI, Stussman BJ, Nahin RL.Regional variation in use of complementary health approaches by U.S. adults. NCHS Data Brief. 2014;(146):1–8.

160. Koning M, Ailabouni R, Gearry RB, Frampton CMA, Barclay ML. Use and predictors of oral complementary and alternative medicine by patients with inammatory bowel disease: a population-based, case-control study. Inamm Bowel Dis. 2013;19(4):767–78.

161. Nguyen GC, Croitoru K, Silverberg MS, Steinhart AH, Weizman AV.Use of complementary and alternative medicine for inammatory bowel disease is associated with worse adherence to con-

338

https://t.me/medicina_free

E. R. Puppala et al.

ventional therapy: the COMPLIANT study. Inamm Bowel Dis. 2016;22(6):1412–7.

162. Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, etal. Systematic review of complementary and alternative medicine treatments in inammatory bowel diseases. J Crohn’s Colitis. 2015;9(1):86–106.

163. Lin SC, Cheifetz AS. The use of complementary and alternative medicine in patients with inammatory bowel disease. Gastroenterol Hepatol. 2018;14(7):415–25.

164. Rossi M, Corradini C, Amaretti A, Nicolini M, Pompei A, Zanoni S, etal. Fermentation of fructooligosaccharides and inulin by bidobacteria: a comparative study of pure and fecal cultures. Appl Environ Microbiol. 2005;71(10):6150–8.

165. Cheifetz AS, Gianotti R, Luber R, Gibson PR.Complementary and alternative medicines used by patients with inammatory bowel diseases. Gastroenterology. 2017;152(2):415–429.e15.

166. Verhoef MJ, Sutherland LR, Brkich L.Use of alternative medicine by patients attending a gastroenterology clinic. CMAJ. 1990;142(2):121–5.

167. Li FX, Verhoef MJ, Best A, Otley A, Hilsden RJ.Why patients with inammatory bowel disease use or do not use complementary and alternative medicine: a canadian national survey. Can J Gastroenterol. 2005;19(9):567–73.

168. Hilsden R. Complementary and alternative medicine use by Canadian patients with inammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003;98(7):1563–8.

169. Burgmann T, Rawsthorne P, Bernstein CN.Predictors of alternative and complementary medicine use in inammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol. 2004;99(5):889–93.

170. Abitbol V, Lahmek P, Buisson A, Olympie A, Poupardin C, Chaussade S, etal. Impact of complementary and alternative medicine on the quality of life in inammatory bowel disease: results from a French national survey. Eur J Gastroenterol Hepatol. 2014;26(3):288–94.

171. Rawsthorne P, Clara I, Graff LA, Bernstein KI, Carr R, Walker JR, et al. The Manitoba inammatory bowel disease cohort study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut. 2012;61(4):521–7.

172. Ceballos C, Bao R, Dunkin D, Song Y, Li XM, Benkov K.Complementary and alternative medicine use at a single pediatric inammatory bowel disease center. Gastroenterol Nurs. 2014;37(4):265–71.

173. Weizman AV, Ahn E, Thanabalan R, Leung W, Croitoru K, Silverberg MS, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inammatory bowel disease. Aliment Pharmacol Ther. 2012;35(3):342–9.

174. Derikx LAAP, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016;30(1):55–71.

175. Frank DN, Amand ALS, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780–5.

176. Jonkers D, Penders J, Masclee A, Pierik M.Probiotics in the management of inammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72(6):803–23.

177. Sartor RB.Microbial inuences in inammatory bowel diseases. Gastroenterology. 2008;134(2):577–94.

178. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, etal. Reduction in diversity of the colonic mucosa associated bacterial microora in patients with active inammatory bowel disease. Gut. 2004;53(5):685–93.

179. Chassaing B, Darfeuillemichaud A.The commensal microbiota and enteropathogens in the pathogenesis of inammatory bowel diseases. Gastroenterology. 2011;140(6):1720–1728.e3.

180. Veerappan GR, Betteridge J, Young PE.Probiotics for the treatment of inammatory bowel disease. Curr Gastroenterol Rep. 2012;14(4):324–33.

181. Fedorak R, Demeria D.Probiotic bacteria in the prevention and the treatment of inammatory bowel disease. Gastroenterol Clin North Am. 2012;41(4):821–42.

182. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, etal. Alteration of gut microbiota in inammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8(3):1–28.

183. Astó E, Méndez I, Audivert S, Farran-Codina A, Espadaler J.The efcacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and metaanalysis. Nutrients. 2019;11(2):293.

184. Sasaki M, Klapproth J-MA.The role of bacteria in the pathogenesis of ulcerative colitis. J Signal Transduct. 2012;2012:704953.

185. Pandey KR, Naik SR, Vakil BV.Probiotics, prebiotics and synbiotics—a review. J Food Sci Technol. 2015;52(12):7577–87.

186. Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, etal. Efcacy of probiotic treatment with Bidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc. 2016;28(1):67–74.

187. Quak SH.Role of probiotics and nutrition in the management of chronic inammatory bowel disease in children. Singapore Med J. 2013;54(4):183–4.

188. Azad MAK, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int. 2018;2018:9478630.

189. Yoshimatsu Y, Mikami Y, Kanai T.Bacteriotherapy for inammatory bowel disease. Inamm Regen. 2021;41(1):3.

190. Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ.Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. 2021;11(12):1–24.

191. Picardo S, Altuwaijri M, Devlin SM, Seow CH.Complementary and alternative medications in the management of inammatory bowel disease. Therap Adv Gastroenterol. 2020;13:1756284820927550.

192. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, etal. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inamm Bowel Dis. 2010;16(8):1286–98.

193. Seth A, Yan F, Polk DB, Rao RK.Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2008;294(4):1060–70.

194. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu LS, etal. Colon-specic delivery of a probiotic-derived soluble protein ameliorates intestinal inammation in mice through an EGFRdependent mechanism. J Clin Invest. 2011;121(6):2242–53.

195. Borruel N, Carol M, Casellas F, Antolín M, De Lara F, Espín E, etal. Increased mucosal tumour necrosis factor α production in Crohn’s disease can be downregulated exvivo by probiotic bacteria. Gut. 2002;51(5):659–64.

196. Basso PJ, Saraiva Câmara NO, Sales-Campos H.Microbial-based therapies in the treatment of inammatory bowel disease—an overview of human studies. Front Pharmacol. 2019;9:1571.

197. McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL.Review article: the gut microbiome in inammatory bowel disease— avenues for microbial management. Aliment Pharmacol Ther. 2018;47(1):26–42.

198. Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M, etal. Maintaining remission of ulcerative colitis with the probi-

Herbal Medicines fortheManagement ofIrritable Bowel Syndrome andConstipation Problem

https://t.me/medicina_free

339

otic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617–23.

199. Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider

S, etal. ESPEN practical guideline: clinical nutrition in inammatory bowel disease. Clin Nutr. 2020;39(3):632–53.

200. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A.The role of probiotic lactic acid bacteria and bidobacteria in the prevention and treatment of inammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015;2015:505878.

201. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, etal. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35(3):327–34.

202. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, etal. Impact on the composition of the faecal ora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13(8):1103–8.

203. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, etal. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202–1209.e1.

204. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–27.

205. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inamm Bowel Dis. 2014;20(9):1562–7.

206. Derwa Y, Gracie DJ, Hamlin PJ, Ford AC.Systematic review with meta-analysis: the efcacy of probiotics in inammatory bowel disease. Aliment Pharmacol Ther. 2017;46(4):389–400.

207. Shen J, Zuo ZX, Mao AP.Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inamm Bowel Dis. 2014;20(1):21–35.

208. Akram W, Garud N, Joshi R. Role of inulin as prebiotics on inammatory bowel disease. Drug Discov Ther. 2019;13(1):1–8.

209. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–12.

210. Van Loo JAE.Prebiotics promote good health: the basis, the potential, and the emerging evidence. J Clin Gastroenterol. 2004;38(6 Suppl):S70–5.

211. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, etal. Expert consensus document: the International Scientic Association for Probiotics and Prebiotics (ISAPP) consensus statement on the denition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502.

212. Basson AR, Lam M, Cominelli F.Complementary and alternative medicine strategies for therapeutic gut microbiota modulation in inammatory bowel disease and their next-generation approaches. Gastroenterol Clin North Am. 2017;46(4):689–729.

213. Damaskos D, Kolios G.Probiotics and prebiotics in inammatory bowel disease: microora “on the scope”. Br J Clin Pharmacol. 2008;65(4):453–67.

214. Govers MJAP, Gannon NJ, Dunshea FR, Gibson PR, Muir JG.Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. Gut. 1999;45(6):840–7.

215. Loganathan P, Anderson A, Hospital NM, Rivers W, Rivers CR.Nutritional management of inammatory bowel diseases: a comprehensive guide. Berlin: Springer; 2016.

216. Nishimura T, Andoh A, Hashimoto T, Kobori A, Tsujikawa T, Fujiyama Y.Cellobiose prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. J Clin Biochem Nutr. 2010;46(2):105–10.

217. Looijer-van Langen MAC, Dieleman LA. Prebiotics in chronic intestinal inammation. Inamm Bowel Dis. 2009;15(3):454–62.

218. Conlon MA, Kerr CA, Mcsweeney CS, Dunne RA, Shaw JM, Kang S, et al. Resistant starches protect against colonic DNA damage and alter microbiota and gene expression in rats fed a western diet. J Nutr. 2012;142(5):832–40.

219. Wang X, Brown IL, Khaled D, Mahoney MC, Evans AJ, Conway PL.Manipulation of colonic bacteria and volatile fatty acid production by dietary high amylose maize (amylomaize) starch granules. J Appl Microbiol. 2002;93(3):390–7.

220. Leitch ECMW, Walker AW, Duncan SH, Holtrop G, Flint HJ.Selective colonization of insoluble substrates by human faecal bacteria. Environ Microbiol. 2007;9(3):667–79.

221. Ze X, Duncan SH, Louis P, Flint HJ. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012;6(8):1535–43.

222. Kanauchi O, Aoata K.Protein, and dietary ber-rich new foodstuff from brewer’s spent grain increased excretion of feces and jejunum mucosal protein content in rats. Biosci Biotechnol Biochem. 1997;61(1):29–33.

223. Kanauchi O, Mitsuyama K, Homma T, Takahama K, Fujiyama Y, Andoh A, etal. Treatment of ulcerative colitis patients by longterm administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med. 2003;12(5):701–4.

224. Videla S, Vilaseca J, Antolín M, García-Lafuente A, Guarner F, Crespo E, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol. 2001;96(5):1486–93.

225. Schneeman BO.Nutritional and health benets of inulin and oligofructose ber, inulin and oligofructose: similarities and differences 1. J Nutr. 1999:1424–7.

226. Kleessen B, Hartmann L, Blaut M.Oligofructose and long-chain inulin: inuence on the gut microbial ecology of rats associated with a human faecal ora. Br J Nutr. 2001;86(2):291–300.

227. Hoentjen F, Welling GW, Harmsen HJM, Zhang X, Snart J, Tannock GW, etal. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microora changes and immunomodulation. Inamm Bowel Dis. 2005;11(11):977–85.

228. Kanauchi O, Iwanaga T, Andoh A, Araki Y, Nakamura T, Mitsuyama K, et al. Dietary ber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. J Gastroenterol Hepatol. 2001;16(2):160–8.

229. Araki Y, Andoh A, Koyama S, Fujiyama Y, Kanauchi O, Bamba T.Effects of germinated barley foodstuff on microora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci Biotechnol Biochem. 2000;64:1794–800.

230. Shiba T, Aiba Y, Ishikawa H, Ushiyama A, Takagi A, Mine T, etal. The suppressive effect of bidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inammatory bowel disease. Microbiol Immunol. 2003;47(6):371–8.

231. Gupta P, Andrew H, Kirschner BS, Guandalini S.Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31(4):453–7.

232. Kanauchi O, Nakamura T, Agata K, Mitsuyama K, Iwanaga T.Effects of germinated barley foodstuff on dextran sulfate sodiuminduced colitis in rats. J Gastroenterol. 1998;33(2):179–88.

233. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y.Prevention of gut inammation by Bidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect. 2003;5(2):115–22.

<<< < Предыдущая 23 24 25 26 27 28 29 30 31 32 33 3435 / 5035 36 37 38 39 40 41 42 43 44 45 46 47 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
30.08.202652 Мб0Книга_5846_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202652 Мб0Книга_5847_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202650 Мб0Книга_5848_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202649 Мб0Книга_5849_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202675 Мб0Книга_585_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202649 Мб0Книга_5850_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202648 Мб0Книга_5851_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202647 Мб0Книга_5852_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202646 Мб0Книга_5853_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202645 Мб0Книга_5854_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202645 Мб0Книга_5855_Библиотеки_им_академика_М_И_Перельмана.pdf